Type of Cancer
Breast Oncology
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.